Plasmapheresis Therapy in Renal Transplant Patients: Five-Year Experience

Güngör, Özlem; Şen, Sait; Kırçelli, Fatih; Yılmaz, Mümtaz; Sarsık, Banu; Özkahya, Mehmet; Hoşçoşkun, Cüneyt; Ok, Ercan; Töz, Hüseyin

doi:10.1016/j.transproceed.2011.03.025

Cited by 27 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These date were not available at the time of placement on the transplant waiting list. In accord with the literature [2,3], in our observations, the 2 extracorporeal procedures had similar effects in terms of graft survival, DSA removal, and cross-match negativity (group A 74% vs 86%; 95% vs 100%). IA was faster to remove DSA than DFPP (negative values; 18 vs 25 days) [4].…”

Section: Discussionsupporting

confidence: 91%

Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation

Pretagostini¹,

Poli²,

Gozzer

et al. 2015

Transplantation Proceedings

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation

Pretagostini¹,

Poli²,

Gozzer

et al. 2015

Transplantation Proceedings

View full text Add to dashboard Cite

“…Plasmapheresis Plasma-based treatments, primarily plasmapheresis, have been used as a first-line treatment for FSGS and for recurrent FSGS after transplantation for nearly 20 years [5,[46][47][48][49][50][51][52][53][54][55][56][57][58][59]. The results of select studies performed since the year 2000 with larger numbers of patients are summarized in Table 2.…”

Section: Treatmentmentioning

confidence: 99%

Recurrent focal segmental glomerulosclerosis after kidney transplantation

2015

View full text Add to dashboard Cite

Focal segmental glomerulosclerosis (FSGS) is an important cause of glomerular disease in children and adolescents and nearly 50 % of affected patients will progress to endstage kidney disease over a 5 to 10-year period. Unfortunately, there is no established treatment for disease in the native kidney. Moreover, up to 55 % of patients develop recurrent disease after receiving a kidney transplant, with a substantially higher risk in patients who have already experienced recurrent disease in a prior transplant. A number of clinical and laboratory factors have been identified as risk factors for this complication. In addition, new investigations into podocyte biology and circulating permeability factors have shed light on the cause of recurrent the disease. While a number of novel therapeutic agents have been applied in the management of this problem, there still is no proven treatment. In this review, we summarize recent advances in the epidemiology, pathophysiology, and treatment of recurrent FSGS in pediatric patients who have received a kidney transplant.

show abstract

“…Güngör et al performed four sessions of plasmapheresis on average in four out of five cases of CAAR and seven sessions of dual filtration plasmapheresis in one patient and reported a response to treatment in one patient, but graft loss in four patients. They initiated plasmapheresis after administration of steroids and ATG (12). We performed five sessions of plasmapheresis and administered IVIg 10 gr after each plasmapheresis in two cases and found that renal functions improved partially after treatment.…”

Section: Discussionmentioning

confidence: 99%

Plasmapheresis in Chronic Active Antibody-Mediated Rejection

Karaveli¹,

Oğuz²,

Yıldırım³

et al. 2015

Turk Neph Dial Transpl

View full text Add to dashboard Cite

Plasmapheresis can be utilized as an adjunct to other methods to desensitize highly-sensitized potential renal transplant recipients or in the case of potential renal transplant recipients with ABO incompatible donors and for the treatment of acute humoral rejections, recurrent focal segmental glomerulosclerosis and thrombotic microangiopathy. In this report, we present our experience with plasmapheresis in two cases of chronic active antibody-mediated rejection. We performed five sessions of plasmapheresis and administered intravenous Ig (IVIg) 10 gr after each plasmapheresis in these cases and found that renal functions improved after the treatment. Chronic active antibody-mediated rejection (CAAR) is difficult to treat and has a negative effect on graft survival. There have been few studies on a limited number of patients treated with a combination of rituximab and IVIg. There is limited knowledge about effects of plasmapheresis on CAAR. Based on treatment outcomes obtained in the two cases presented here, it can be emphasized that plasmapheresis is one of the most important treatment alternatives in CAAR, a condition that affects graft survival. KEY wORdS: Plasmapheresis, Rejection, Transplantation özPlazmaferez tedavisi böbrek nakil hastalarında ABO uyuşmazlığı durumunda, yüksek sensitize hastalarda nakil öncesi, akut humoral rejeksiyonlarda, reküren fokal segmental glomeruloskleroz ve trombotik mikroanjiopati olgularında diğer tedavilere ek olarak uygulanabilir. Bu yazıda canlı donörden böbrek nakli yapılmış iki hastamızda kronik humoral rejeksiyonda plazmaferez deneyimimiz anlatılmaktadır. Biz iki hastamızda da 5 seans plazmaferez ve her plazmaferez sonrası 10 gr intravenöz immünglobulin tedavisi uyguladık. Tedavi sonrası böbrek fonksiyonlarında belirgin düzelme saptandı. Kronik aktif antikor aracılı rejeksiyonun (KAAR), tedavisi güç olup greft sağ kalımını önemli ölçüde olumsuz etkiler. İntravenöz immünglobulin ve rituksimabın yararı gösterilmemiş olup plazmaferez tedavisi ile bilgiler sınırlıdır. Biz iki vakamızda da plazmaferez tedavisine yanıt alarak; greft sağ kalımını olumsuz etkileyen KAAR tedavisinde plazmaferezin önemli tedavi seçeneklerinden biri olabileceğini vurguladık.anahtar sözcüKler: Plazmaferez, Rejeksiyon, Transplantasyon

show abstract

Plasmapheresis Therapy in Renal Transplant Patients: Five-Year Experience

Cited by 27 publications

References 18 publications

Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation

Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation

Recurrent focal segmental glomerulosclerosis after kidney transplantation

Plasmapheresis in Chronic Active Antibody-Mediated Rejection

Contact Info

Product

Resources

About